20451-50-7

Upstream product

• 5451-55-8 4-tert-butylcyclohexanecarboxylic acid 

Downstream Products

• 25774-37-2 4-tert.-Butyl-cyclohexancarbonsaeure-anhydrid 
• 28125-13-5 1-(4-tert-Butyl-cyclohexyl)-2-diazo-ethanone 
• 28125-14-6 1-(4-tert-Butyl-cyclohexyl)-2-diazo-ethanone 
• 174271-42-2 trans-4-tert-butyl-N-allylcyclohexanecarboxamide 
• 14033-64-8 (R)-(4-tert-butylcyclohexylidene)ethane 
• 172536-19-5 4-tert-Butyl-1-((S)-1-hydroxy-ethyl)-cyclohexanecarboxylic acid 
• 172536-18-4 (4S,5R)-1-[4-tert-Butyl-1-((S)-1-hydroxy-ethyl)-cyclohexanecarbonyl]-3,4-dimethyl-5-phenyl-imidazolidin-2-one 
• 84856-22-4 Benzenesulfonic acid 2-(4-tert-butyl-cyclohexyl)-2-oxo-ethyl ester 
• 84856-21-3 Benzenesulfonic acid 2-(4-tert-butyl-cyclohexyl)-2-oxo-ethyl ester 
• 863769-04-4 4-tert-butyl-cyclohexanecarboxylic acid pyridin-4-ylamide 
• 477879-68-8 4-tert-butyl-N-[1-(3-cyclopropyl-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)propyl]cyclohexanecarboxamide 
• 477879-69-9 4-tert-butyl-N-[1-(3-cyclopentyl-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)propyl]cyclohexanecarboxamide 
• 477879-70-2 4-tert-butyl-N-[1-(3-tert-butyl-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)propyl]cyclohexanecarboxamide 
• 1037834-23-3 1-{1-[2-(4-tert-butylcyclohexyl)-2-oxoethyl]piperidin-4-yl}-6-fluoro-N-methyl-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide 

Relevant academic research and scientific papers

Synthesis and Anti-hyperglycemic Activity of New C-Glucoside SGLT2 Inhibitors

A series of new trans-1-{4-methoxy-3-[(4-substituted cyclohexyl) methyl]phenyl}-1-deoxy-β-D-glucopyranoses (12a-12d) was synthesized. The structures of synthesized compounds were confirmed by 1H NMR and HR-MS data. The synthesis of compounds bearing large

Nitrile group containing phenyl trans-cyclohexane amide compound and use thereof

The invention belongs to the field of medicines associated with thrombotic diseases, and particularly relates to a nitrile group and phenyl group-containing PAR-1 (pretease activated receptor-1) antagonist and application of antagonist in preparation of medicines for treating thrombotic diseases, wherein the nitrile group and phenyl group-containing PAR-1 antagonist has a structure of a formula (I) as shown in the specification.

Kinetic studies of the epimerization of diastereomeric pyrylium salts

Chiral pyrylium salts are almost unknown in the literature, and none that are epimerizable have been reported prior to our work. Herein, we report two new epimerizable pyryliums and the kinetics of the diastereomeric equilibration of these and one other e

Synthesis of new chiral pyrylium salts and their phosphinine and pyridine derivatives

Despite their versatility, chiral pyryliums are almost unknown in the literature. Reported here is the synthesis of several new chiral pyrylium salts and the corresponding pyridines and phosphinines. This work more than doubles the number of reported chir

INHIBITORS OF SERINE PALMITOYLTRANSFERASE

This invention provides compounds of the formula (I) useful in the inhibition or modulation of serine palmitoyl transferase and their use in methods of treatment or amelioration of type 2 diabetes, type 1 diabetes, insulin resistance, the effects of obesity, metabolic syndrome (sometimes referred to as Syndrome X), impaired glucose tolerance, Cushing's disease, cardiovascular disease, prothrombotic conditions, myocardial infarction, hypertension, congestive heart failure, cardiomyopathy, atherosclerosis, dyslipidemia, sepsis, liver damage, retinal degenerative disorders, cachexia, emphysema, hepatitis C infections, HIV infections and inflammatory disorders and useful in methods for raising HDL plasma levels in a mammal. The compounds of this invention can also be used to prevent damage or loss of pancreatic islet beta cells (such as in the case of pancreatic beta cell apoptosis, including those related to insulin-dependent diabetes mellitus).

KINASE INHIBITORS

The invention provides the use of a compound or a composition comprising said compound for inhibiting the activity of at least one kinase, other than ROCK kinase, in vitro or in vivo, pharmaceutical and/or veterinary compositions comprising such compounds, medical and veterinary uses of such compounds and the compounds themselves.

Rearrangements of substituted 3-aza-1,2,5-hexatrienes. 3. The scope and versatility of an extremely mild 3-aza-Cope reaction

An investigation of the [3,3]-sigmatropic reaction of substituted 3-aza-1,2,5-hexatrienes to give 4-pentenenitriles is presented. This reaction has been found to occur under a wide variety of reactions conditions (10 are reported) starting from readily av